Literature DB >> 22576662

Thyroid hormone receptors promote metastasis of human hepatoma cells via regulation of TRAIL.

H-C Chi1, S-L Chen, C-J Liao, C-H Liao, M-M Tsai, Y-H Lin, Y-H Huang, C-T Yeh, S-M Wu, Y-H Tseng, C-Y Chen, C-Y Tsai, I-H Chung, W-J Chen, K-H Lin.   

Abstract

Although accumulating evidence has confirmed the important roles of thyroid hormone (T(3)) and its receptors (TRs) in tumor progression, the specific functions of TRs in carcinogenesis remain unclear. In the present study, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) was directly upregulated by T(3) in TR-overexpressing hepatoma cell lines. TRAIL is an apoptotic inducer, but it can nonetheless trigger non-apoptotic signals favoring tumorigenesis in apoptosis-resistant cancer cells. We found that TR-overexpressing hepatoma cells treated with T(3) were apoptosis resistant, even when TRAIL was upregulated. This apoptotic resistance may be attributable to simultaneous upregulation of Bcl-xL by T(3), because (1) knockdown of T(3)-induced Bcl-xL expression suppressed T(3)-mediated protection against apoptosis, and (2) overexpression of Bcl-xL further protected hepatoma cells from TRAIL-induced apoptotic death, consequently leading to TRAIL-promoted metastasis of hepatoma cells. Moreover, T(3)-enhanced metastasis in vivo was repressed by the treatment of TRAIL-blocking antibody. Notably, TRAIL was highly expressed in a subset of hepatocellular carcinoma (HCC) patients, and this high-level expression was significantly correlated with that of TRs in these HCC tissues. Together, our findings provide evidence for the existence of a novel mechanistic link between increased TR and TRAIL levels in HCC. Thus, TRs induce TRAIL expression, and TRAIL thus synthesized acts in concert with simultaneously synthesized Bcl-xL to promote metastasis, but not apoptosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576662      PMCID: PMC3469053          DOI: 10.1038/cdd.2012.58

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  38 in total

Review 1.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

2.  Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation.

Authors:  M Ehrenschwender; D Siegmund; A Wicovsky; M Kracht; O Dittrich-Breiholz; V Spindler; J Waschke; H Kalthoff; A Trauzold; H Wajant
Journal:  Cell Death Differ       Date:  2010-04-09       Impact factor: 15.828

3.  A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells.

Authors:  Christian D Fingas; Boris R A Blechacz; Rory L Smoot; Maria E Guicciardi; Justin Mott; Steve F Bronk; Nathan W Werneburg; Alphonse E Sirica; Gregory J Gores
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

4.  Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer.

Authors:  Chia-Jung Liao; Tzu-I Wu; Ya-Hui Huang; Ting-Chang Chang; Chia-Siu Wang; Ming-Ming Tsai; Chyong-Huey Lai; Ying Liang; Shih-Ming Jung; Kwang-Huei Lin
Journal:  Cancer Sci       Date:  2011-10-17       Impact factor: 6.716

5.  Cooperation between the thyroid hormone receptor TRalpha1 and the WNT pathway in the induction of intestinal tumorigenesis.

Authors:  Elsa Kress; Seham Skah; Maria Sirakov; Julien Nadjar; Nicolas Gadot; Jean-Yves Scoazec; Jacques Samarut; Michelina Plateroti
Journal:  Gastroenterology       Date:  2010-01-28       Impact factor: 22.682

6.  Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer.

Authors:  Martin Grimm; Mia Kim; Andreas Rosenwald; Burkhard H A von Raden; Burkhard von Rahden; Igor Tsaur; Eva Meier; Uwe Heemann; Christoph-Thomas Germer; Martin Gasser; Ana Maria Waaga-Gasser
Journal:  Eur J Cancer       Date:  2010-06-25       Impact factor: 9.162

7.  Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells.

Authors:  S-M Wu; Y-H Huang; C-T Yeh; M-M Tsai; C-H Liao; W-L Cheng; W-J Chen; K-H Lin
Journal:  Oncogene       Date:  2011-01-10       Impact factor: 9.867

8.  Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces chemotactic migration of monocytes via a death receptor 4-mediated RhoGTPase pathway.

Authors:  Wei Wei; Dongsheng Wang; Juan Shi; Yang Xiang; Yaxi Zhang; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  Mol Immunol       Date:  2010-07-16       Impact factor: 4.407

9.  Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.

Authors:  F Ozawa; H Friess; J Kleeff; Z W Xu; A Zimmermann; M S Sheikh; M W Büchler
Journal:  Cancer Lett       Date:  2001-02-10       Impact factor: 8.679

10.  The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell.

Authors:  Dong-Hui Zhou; Anna Trauzold; Christian Röder; Gang Pan; Cheng Zheng; Holger Kalthoff
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2008-04
View more
  18 in total

Review 1.  Thyroid hormone and anti-apoptosis in tumor cells.

Authors:  Hung-Yun Lin; Gennadi V Glinsky; Shaker A Mousa; Paul J Davis
Journal:  Oncotarget       Date:  2015-06-20

2.  Thyroid hormone protects hepatocytes from HBx-induced carcinogenesis by enhancing mitochondrial turnover.

Authors:  H-C Chi; S-L Chen; S-L Lin; C-Y Tsai; W-Y Chuang; Y-H Lin; Y-H Huang; M-M Tsai; C-T Yeh; K-H Lin
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

3.  Thyroid hormone suppresses hepatocarcinogenesis via DAPK2 and SQSTM1-dependent selective autophagy.

Authors:  Hsiang-Cheng Chi; Shen-Liang Chen; Chung-Ying Tsai; Wen-Yu Chuang; Ya-Hui Huang; Ming-Ming Tsai; Sheng-Ming Wu; Cheng-Pu Sun; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Autophagy       Date:  2016-09-21       Impact factor: 16.016

Review 4.  Thyroid hormone actions in liver cancer.

Authors:  Sheng-Ming Wu; Wan-Li Cheng; Crystal D Lin; Kwang-Huei Lin
Journal:  Cell Mol Life Sci       Date:  2012-09-06       Impact factor: 9.261

Review 5.  Recurrence of differentiated thyroid carcinoma during full TSH suppression: is the tumor now thyroid hormone dependent?

Authors:  Paul J Davis; Aleck Hercbergs; Mary K Luidens; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2014-10-08       Impact factor: 3.869

6.  The impact of thyroid hormones on patients with hepatocellular carcinoma.

Authors:  Matthias Pinter; Lukas Haupt; Florian Hucke; Simona Bota; Theresa Bucsics; Michael Trauner; Markus Peck-Radosavljevic; Wolfgang Sieghart
Journal:  PLoS One       Date:  2017-08-03       Impact factor: 3.240

7.  Upregulation of c-FLIP-short in response to TRAIL promotes survival of NSCLC cells, which could be suppressed by inhibition of Ca2+/calmodulin signaling.

Authors:  V O Kaminskyy; O V Surova; T Piskunova; I B Zborovskaya; E M Tchevkina; L Andera; B Zhivotovsky
Journal:  Cell Death Dis       Date:  2013-03-07       Impact factor: 8.469

Review 8.  Molecular functions of thyroid hormones and their clinical significance in liver-related diseases.

Authors:  Hsiang Cheng Chi; Cheng-Yi Chen; Ming-Ming Tsai; Chung-Ying Tsai; Kwang-Huei Lin
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

9.  Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells.

Authors:  Keren Cohen; Nir Flint; Shachar Shalev; Daniel Erez; Tal Baharal; Paul J Davis; Aleck Hercbergs; Martin Ellis; Osnat Ashur-Fabian
Journal:  Oncotarget       Date:  2014-08-15

10.  Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway.

Authors:  Hsiang-Cheng Chi; Shen-Liang Chen; Yi-Hung Cheng; Tzu-Kang Lin; Chung-Ying Tsai; Ming-Ming Tsai; Yang-Hsiang Lin; Ya-Hui Huang; Kwang-Huei Lin
Journal:  Cell Death Dis       Date:  2016-08-04       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.